Sanofi’s Sarclisa (isatuximab) Receives NICE Recommendation for Patients with Multiple Myeloma
Pfizer partners with BioNTech to develop vaccine for Influenza for $425M
Pfizer partners with BioNTech to develop vaccine for Influenza for $425M
Shots:
- Pfizer is planning to pay $120M upfront along with $305M milestone payment
- BioNTech will also receive double-digit royalties post sales whereas, Pfizer acquires small stakes in BioNTech as part of upfront payment
- Pfizer plans to do further trials and commercialization of vaccines post completion of the first clinical study by BioNTech
Click here to read full press release/ article | Ref: Reuters | Image: Twitter
